Exclusive Online Content
Centogene & Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases
Centogene N.V. and Twist Bioscience Corporation recently announced they have signed a contract to collaborate on the development and commercialization of custom assay kits for rare diseases…..
Acer Therapeutics & Relief Therapeutics Announce FDA Acceptance for Filing of NDA
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics Holding SA recently announced the US FDA has accepted for filing the New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for the….
Agenus to Receive $20-Million Milestone Payment From Bristol Myers Squibb With Dosing of First Patient
Agenus Inc. recently announced it has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb for AGEN1777, an Fc-enhanced bispecific….
Metrics Contract Services Enters Partnership to Develop Oncology Drug
Metrics Contract Services, the US-based contract pharmaceutical development and manufacturing division of Mayne Pharma, recently announced the signing of a development and manufacturing agreement with….
MilliporeSigma Launches Excipient Technology Platform for Viscosity Reduction of Protein-Based Therapeutics
MilliporeSigma has recently launched a new Viscosity Reduction Excipient Platform to reduce the viscosity and help overcome manufacturing and formulation challenges associated with….
MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza in Pediatric Population
MannKind Corporation recently announced the enrollment of the first pediatric patient in the INHALE-1 study. The multi-center study will evaluate the efficacy and safety of….
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
InMed Pharmaceuticals Inc. recently announced it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time….
Avacta Group Announces Achievement of Preclinical Development Milestone in LG Chem Life Sciences Partnership
Avacta Group plc recently announced a preclinical development milestone has been achieved in the multi-target therapeutics development partnership with LG Chem Life Sciences, the life sciences division of the South Korean LG Group, triggering an….
Novigenix & Radbound University Medical Center Discover the First Blood-Based ImmunoTranscriptomic Biomarkers for Response to Anti-PD-1 Therapy
Novigenix SA recently announced release of the article Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. Immune checkpoint inhibitors (ICIs) have become….
Genetron Health & IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline
Genetron Holdings Limited recently announced a partnership with IMPACT Therapeutics in which the two parties will cooperate together on research and development for synthetic lethal inhibitors that are based on….
Evelo Biosciences Announces Positive Phase 2 Clinical Data With EDP1815 in Psoriasis
Evelo Biosciences, Inc. recently announced positive data from its Phase 2 study evaluating EDP1815 versus placebo for the treatment of mild and moderate psoriasis. A statistically significant reduction in the….
ESCP Models - Hepatitis C Medications (Part 1)
In a series of four articles earlier this year, the principles of the ESCP Analysis process were outlined with a few simple to understand examples. To better explain the application of the process, I have summarized the evolution of Hepatitis C (HCV) treatment from naked Interferon alpha treatment through to the latest….
Credence MedSystems Secures $39.9 Million Financing to Enable Scaling of Innovative Drug Delivery & Connected Health Systems
Credence MedSystems, Inc. recently announced it has closed a funding round with gross proceeds of $39.9 million. Sources of funding include strategic investments from Novartis Pharma AG,….
Novartis Announces Collaboration on HARMONIA, a Phase 3, Head-to-Head Trial Evaluating Kisqali Versus Ibrance in Patients With HR+/HER2- Advanced Breast Cancer
Novartis recently announced a collaboration with SOLTI Innovative Cancer Research (SOLTI) on HARMONIA, an international, randomized, Phase 3, multicenter, open-label study of….
Clarus Therapeutics & McGill University Announce Exclusive Worldwide Licensing Agreement to Develop & Commercialize Technology to Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies
Clarus Therapeutics Holdings, Inc. and McGill University recently announced a licensing agreement whereby Clarus will develop and commercialize McGill’s proprietary technology designed to treat….
FDA Approves Samsung Bioepis & Biogen’s BYOOVIZ (SB11), LUCENTIS Biosimilar (ranibizumab-nuna)
Samsung Bioepis Co., Ltd. and Biogen Inc. recently announced the US FDA has approved BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab) for the treatment of neovascular….
SomaLogic Announces Strategic Collaboration With UPMC to Tailor Clinical Care Through Proteomics Technology
SomaLogic recently announced a strategic collaboration with leading health system UPMC to explore how the large-scale study of proteins and….
ProQR Announces Axiomer RNA Editing Licensing & Research Collaboration With Lilly
ProQR Therapeutics N.V. recently announced a global licensing and research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and….
Longeveron Partners With Kinesiometrics to Create & Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell Therapy
Longeveron Inc. has entered into an agreement with Kinesiometrics Inc., to provide a cutting-edge, digital data-driven solution for objective real-time measurement of functional capacity and quality….
AzurRx BioPharma Announces Acquisition of First Wave Bio & its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
AzurRx BioPharma, Inc. recently announced it has entered a definitive agreement to acquire First Wave Bio, Inc. in a stock and cash transaction valued at….
